한글목차

세계 뇌 바이오마커 시장의 미래는 병원, 실험실, 외래 수술 센터, 진단 연구소 등의 시장에서 기회로 인해 유망합니다. 세계 뇌 바이오마커 시장은 2025년부터 2031년까지 7.4%의 CAGR로 2031년까지 약 180억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 신경 질환의 정밀 진단 기술에 대한 수요 증가, 정신 질환의 조기 발견 및 관리를 지원하는 바이오마커에 대한 수요 증가, 맞춤형 의료에 대한 수요 증가, 뇌 바이오마커는 신경 질환 환자의 맞춤형 치료 계획 수립에 활용될 수 있습니다. 뇌 바이오마커는 신경질환 환자의 맞춤형 치료계획 수립에 활용될 수 있습니다.

• 제품 유형별로는 바이오마커 검사 키트가 진단 및 연구에서 중요한 역할을 하고 다양한 신경 질환 및 관련 바이오마커를 식별하고 정량화하는 신뢰할 수 있고 효과적인 기술을 제공하기 때문에 예측 기간 동안에도 큰 비중을 차지할 것으로 루킨텔은 예측했습니다.
• 최종 용도별로는 병원이 바이오마커를 조기 질병 식별, 치료 모니터링 등 다양한 목적으로 사용함으로써 신속한 개입과 맞춤형 치료 요법을 가능하게 하는 바이오마커가 가장 큰 비중을 차지할 것으로 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 큰 지역이 될 것으로 보입니다.

뇌 바이오마커 시장의 전략적 성장 기회

뇌 바이오마커 시장은 연구 및 기술 발전, 신경질환 유병률 증가를 배경으로 몇 가지 전략적 성장 기회를 창출하고 있습니다.

• 알츠하이머병 조기 진단 : 알츠하이머병 조기 진단 도구의 필요성이 큰 성장 기회를 창출하고 있습니다. 바이오마커는 조기 진단에 도움을 주어 적시에 개입하고 환자의 예후를 개선할 수 있도록 돕습니다.
• 치료 옵션의 발전 : 맞춤형 의료로의 전환은 바이오마커를 기반으로 한 치료의 길을 열어가고 있습니다. 특정 바이오마커 프로파일에 기반한 치료법 개발은 보다 효과적이고 표적화된 치료를 가능하게 하고 부작용의 위험을 줄일 수 있습니다.
• 신경 퇴행성 질환 연구에 대한 투자 : 파킨슨병, 다발성 경화증과 같은 질환에 대한 관심이 높아지면서 뇌 바이오마커 연구에 대한 투자가 증가하고 있습니다. 이 분야에서 발견된 새로운 바이오마커는 이러한 질환의 진단과 모니터링을 보다 효과적으로 수행하는 데 도움이 될 수 있습니다.
• 연구 협력 : 학계, 연구기관, 업계 관계자들 간의 협력 관계 강화는 바이오마커의 발견과 적용을 가속화하고 있습니다. 이러한 파트너십은 연구 일정을 단축하고 새로운 진단 도구를 신속하게 시장에 출시하는 데 도움이 되고 있습니다.
• 임상 적용 확대 : 바이오마커의 임상 적용에 대한 요구가 증가하고 있습니다. 바이오마커가 보다 광범위하게 사용되는 것이 검증됨에 따라 다양한 신경질환의 진단 및 관리에 바이오마커를 적용할 수 있는 기회가 늘어날 것으로 보입니다.

이러한 기회는 뇌 바이오마커 시장의 지속적인 성장 가능성을 명확히 하고, 신경학 분야의 새로운 발견과 환자 치료 강화의 길을 제공합니다.

뇌 바이오마커 시장 활성화 요인 및 과제

뇌 바이오마커 제품의 상용화는 사용 가능한 기술, 사회경제적 및 규제 환경 등 많은 촉진요인과 도전에 영향을 받습니다. 시장에서 사업을 전개하기 위해서는 이러한 역학관계를 파악하는 것이 중요합니다.

뇌 바이오마커 시장을 이끄는 요인은 다음과 같습니다:

• 기술 발전 : 바이오마커 검출과 그 분석의 원리, 방법, 수단의 끊임없는 기술 개선은 시장의 성장을 보장하고 있습니다. 새로운 식별자 및 진단적 상상력의 개발, 유전체 및 단백질체학 기술은 진단의 민감도와 특이성을 향상시킵니다.
• 연구 자금의 증가 : 신경과학 및 신경질환 연구에 대한 투자 증가는 뇌 바이오마커의 성장을 촉진하고 있습니다. 임상시험에 대한 자금 조달은 일반적으로 많은 금액이 투입되기 때문에 효과적인 의사결정으로 이어지는 검증 과정이 지원되고 촉진됩니다.
• 신경질환의 발생률 증가 : 알츠하이머병과 파킨슨병의 신규 환자가 증가하는 추세로 효과적인 진단 솔루션이 요구되고 있습니다. 이러한 경우, 바이오마커는 임상적 발견 및 상태 모니터링에 도움이 될 수 있습니다.
• 바이오마커 기반 검사에 대한 수요 증가 : 맞춤형 의료의 확산으로 바이오마커 기반 진단이 요구되고 있습니다. 임상 진료로서의 종양학은 바이오마커를 통해 특정 환자의 필요에 맞는 치료 접근법이 임상 결과를 개선할 수 있기 때문에 바이오마커의 혜택을 누릴 수 있습니다.
• 보조금 신청에 대한 공동 지원 : 학계, 산업계, 임상 파트너와의 효과적인 협력 관계를 통한 병렬 발명이 뇌 바이오마커 개발 노력을 뒷받침하고 있습니다. 이러한 협력 관계는 자원의 공유를 촉진하고, 진전 속도를 높이는 데 도움이 되고 있습니다.

뇌 바이오마커 시장의 과제는 다음과 같습니다:

• 규제 장벽 : 바이오마커 기반 진단기기의 승인은 시간과 비용이 많이 소요됩니다. 승인 절차에 시간이 오래 걸리면, 필요한 환자에게 새로운 진단 도구의 제공이 지연될 수 있습니다.
• 재정적 장벽 : 뇌 바이오마커의 개발 및 검증에 따른 높은 비용은 특히 자금력이 부족한 중소기업에 큰 부담으로 작용합니다. 이로 인해 진전이 지연되고 혁신적인 솔루션에 대한 접근이 제한될 수 있습니다.
• 시장 경쟁 : 뇌 바이오마커 시장에 진입하는 기업이 증가하면서 경쟁이 심화되고 있습니다. 기업은 경쟁력을 유지하고 시장 점유율을 확보하기 위해 제품과 서비스를 차별화해야 합니다.

시장 촉진요인 및 과제를 극복하는 것이 뇌 바이오마커 분야에서 성공할 수 있는 열쇠입니다.

신흥국들은 각각 신경질환의 진단 정확도 향상과 치료 중재에 초점을 맞춰 뇌 바이오마커 개발에 큰 기여를 하고 있습니다.

목차

제1장 주요 요약

제2장 세계의 뇌 바이오마커 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2019년부터 2031년까지 시장 동향과 예측 분석

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 뇌 바이오마커 시장 동향(2019-2024년)과 예측(2025-2031년)
• 제품 유형별 : 세계의 뇌 바이오마커 시장
  • 바이오마커 검사 키트
  • 바이오마커 분석기
• 질환 적응증별 : 세계의 뇌 바이오마커 시장
  • 뇌졸중
  • 운동신경질환과 근위축성측색경화증
  • 알츠하이머병 및 기타 치매
  • 파킨슨병
  • 헌팅턴병
• 용도별 : 세계의 뇌 바이오마커 시장
  • 진단
  • 의약품 발견과 개발
  • 기타
• 최종 용도별 : 세계의 뇌 바이오마커 시장
  • 병원
  • 조사실
  • 외래 수술 센터
  • 진단 검사실
  • 기타

제4장 2019년부터 2031년까지 지역별 시장 동향과 예측 분석

• 지역별 : 세계의 뇌 바이오마커 시장
• 북미의 뇌 바이오마커 시장
• 유럽의 뇌 바이오마커 시장
• 아시아태평양의 뇌 바이오마커 시장
• 기타 지역의 뇌 바이오마커 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 제품 유형별 세계의 뇌 바이오마커 시장 성장 기회
  • 질환 적응증별 세계의 뇌 바이오마커 시장 성장 기회
  • 용도별 세계의 뇌 바이오마커 시장 성장 기회
  • 최종 용도별 세계의 뇌 바이오마커 시장 성장 기회
  • 지역별 세계의 뇌 바이오마커 시장 성장 기회
• 세계의 뇌 바이오마커 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 뇌 바이오마커 시장 능력 확대
  • 세계의 뇌 바이오마커 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

영문목차

The future of the global brain biomarker market looks promising with opportunities in the hospital, research laboratory, ambulatory surgical center, and diagnostic laboratory markets. The global brain biomarker market is expected to reach an estimated $18 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the increased need for precise diagnostic techniques in neurological diseases, the rising need for biomarkers to aid in the early identification and management of mental health issues, and the growing demand for personalized medicine, brain biomarkers can be used to develop personalized treatment plans for patients with neurological disorders.

• Lucintel forecasts that, within the product type category, biomarker test kit will remain the larger segment over the forecast period due to their critical role in diagnostics and research, offering a reliable and effective technique to identify and quantify biomarkers linked with diverse neurological disorders.
• Within the end use category, hospitals will remain the largest segment due to hospitals use biomarkers for a variety of objectives, including early illness identification and treatment monitoring, which allows for prompt interventions and tailored care regimens.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Brain Biomarker Market

The brain biomarker market is undergoing significant transformation driven by technological advancements, research funding, and the growing emphasis on personalized medicine. These trends are reshaping the way neurological disorders are diagnosed, monitored, and treated.

• AI and Machine Learning Integration: Artificial intelligence (AI) and machine learning are revolutionizing the brain biomarker field by analyzing complex datasets more efficiently. These technologies enhance the discovery of new biomarkers and improve the predictive accuracy of existing ones, simplifying diagnosis and treatment plans.
• Personalized Medicine Approach: Personalized medicine is gaining traction in the brain biomarker market, with treatments increasingly tailored to individual biomarker profiles. By leveraging genetic profiling and biomarker analysis, healthcare providers can customize treatments to improve patient outcomes and minimize adverse effects.
• Increased Investment in Research: Growing funding from both public and private sectors is fueling research into neurological diseases, leading to the discovery of new biomarkers. This investment is critical for early detection, more accurate diagnosis, and more effective treatments.
• Collaboration Between Sectors: Enhanced collaboration between academia, industry, and healthcare organizations is accelerating biomarker development. These partnerships facilitate the transfer of knowledge and resources, leading to faster development and implementation of biomarker-based diagnostics and treatments.
• Regulatory Advancements: Regulatory landscapes are evolving, particularly in Western countries, where there is a growing push to incorporate biomarkers into clinical applications. Relaxation of market access barriers is helping to expedite the use of biomarkers in clinical practice.

These trends are significantly impacting the brain biomarker market, improving both the speed and accuracy of diagnosis and leading to more effective therapeutic interventions for neurological diseases.

Recent Developments in the Brain Biomarker Market

Recent advancements in the brain biomarker market are a result of ongoing technological progress and increased research efforts, particularly in the areas of biomarker discovery, validation, and clinical application.

• FDA Approvals for Novel Biomarkers: Recent FDA approvals of blood-based biomarkers for Alzheimer's disease have opened up new avenues for early detection and treatment. These innovations offer the potential for earlier interventions and more targeted therapeutic strategies.
• AI-Based Biomarker Discovery: The integration of AI in the biomarker discovery process is transforming how large datasets, including genetic and neuroimaging data, are analyzed. AI-driven approaches can identify novel biomarkers with higher predictive potential, enabling earlier diagnosis and better treatment outcomes.
• Collaborative Research Ventures: The convergence of academic institutions, biotech companies, and healthcare providers is accelerating the pace of biomarker development. These partnerships are focused on translating biologically validated biomarkers into clinical practice, bringing innovations to market faster.
• Focus on Proteomics and Genomics: Proteomic and genomic technologies are playing a central role in the search for brain biomarkers. These techniques are uncovering potential biomarkers that can be used for the early detection and monitoring of neurodegenerative diseases.
• Improved Imaging Modalities: Advances in imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are enhancing the sensitivity, specificity, and quantification of cerebral biomarkers. These imaging advancements are crucial for better understanding and diagnosing brain diseases.

These recent developments are propelling the brain biomarker market forward, with improvements in analytical capabilities and clinical applications leading to better diagnostic and therapeutic strategies.

Strategic Growth Opportunities for Brain Biomarker Market

Several strategic growth opportunities are emerging within the brain biomarker market, driven by advances in research, technology, and the rising incidence of neurological disorders.

• Alzheimer's Disease Early Diagnosis: The need for early diagnostic tools for Alzheimer's disease is creating significant growth opportunities. Biomarkers can aid in early diagnosis, allowing for timely intervention and improved patient outcomes.
• Advancing Treatment Options: The shift toward personalized medicine is paving the way for biomarker-based therapies. Developing treatments based on specific biomarker profiles will enable more effective and targeted therapies, reducing the risk of side effects.
• Investments in Neurodegenerative Disease Research: Growing concerns about diseases like Parkinson's and multiple sclerosis are driving investments in brain biomarker research. New biomarkers discovered in these areas will aid in diagnosing and monitoring these conditions more effectively.
• Research Collaborations: Increasing collaboration between academia, research organizations, and industry players is accelerating biomarker discovery and application. These partnerships are helping to shorten research timelines and bring new diagnostic tools to market more quickly.
• Expanding Clinical Applications: There is a growing demand for the integration of biomarkers into clinical practice. As biomarkers are validated for broader use, there will be more opportunities to apply them in the diagnosis and management of various neurological diseases.

These opportunities underscore the potential for continued growth in the brain biomarker market, offering avenues for new discoveries and enhanced patient care in the field of neurology.

Brain Biomarker Market Driver and Challenges

The commercialization of brain biomarker products is influenced by a number of drivers and challenges such as available technology, and socio-economic and regulatory environment. It is important to know these dynamics in order to operate in the market.

The factors responsible for driving the brain biomarker market include:

• Technological Advancements: The constant technological improvement of principles, methods, and means of biomarker detection and their analysis is ensuring market growth. Development of new identifiers and diagnostic imagination, genomic and proteomic technologies improves sensitivity and specificity in diagnosis.
• Increased Research Funding: The growth in the investment allocated for neuroscience and neurological disorder studies is promoting the growth of brain biomarkers. Financing of clinical trials is usually heavy, and this subsidizes and hastens the process of verification leading to effective decision-making.
• Rising Incidence of Neurological Disorders: New cases of Alzheimer's and Parkinson's diseases are on the rise which in turn pushes for effective diagnostic solutions. Biomarkers, in such cases, help in clinical detection as well as monitoring of the condition.
• Increasing Demand For Biomarker Based Tests: The increase in the adoption of personalized medicine has seen biomarker based diagnostics become sought after. Oncology as a clinical practice benefits from biomarkers since treatment approaches are catered to the needs of specific patients improving clinical outcomes.
• Jointly Helping To Apply For The Grant: Parallel inventions through effective collaborations with academic, industrial, and clinical partners are supporting brain biomarkers developmental efforts. These cooperative relationships foster resource sharing which helps in speeding up progress.

Challenges in the brain biomarker market are:

• Regulatory Barriers: Obtaining regulatory approval for biomarker-based diagnostic devices can be time-consuming and costly. Slow approval processes can delay the availability of new diagnostic tools to patients in need.
• Financial Barriers: The high costs associated with the development and validation of brain biomarkers pose a challenge, particularly for smaller companies with limited financial resources. This can slow down progress and limit access to innovative solutions.
• Market Competition: The growing number of companies entering the brain biomarker market is intensifying competition. Companies must differentiate their products and services to maintain a competitive edge and capture market share.

Navigating these challenges while capitalizing on market drivers will be key to the success of companies in the brain biomarker space.

List of Brain Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies brain biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the brain biomarker companies profiled in this report include-

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

Brain Biomarker by Segment

The study includes a forecast for the global brain biomarker market by product type, disease indication, application, end use, and region.

Brain Biomarker Market by Product Type [Analysis by Value from 2019 to 2031]:

• Biomarker Test Kits
• Biomarker Analyzers

Brain Biomarker Market by Disease Indication [Analysis by Value from 2019 to 2031]:

• Stroke
• MND & ALS
• Alzheimer's Disease & Other Dementias
• Parkinson's Disease
• Huntington's Disease

Brain Biomarker Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnosis
• Drug Discovery and Development
• Others

Brain Biomarker Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Research Laboratories
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

Brain Biomarker Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Brain Biomarker Market

The brain biomarker market is growing globally, with key contributions from countries like the United States, China, Germany, India, and Japan. Each of these countries is making strides in the development of brain biomarkers and their clinical applications.

• United States: The U.S. is leading in brain biomarker research and development, particularly in the area of Alzheimer's disease. Recent FDA approvals for blood-based amyloid-beta biomarkers have paved the way for new diagnostic methods. The use of AI in biomarker analysis is also growing, enhancing diagnostic accuracy and speed.
• China: China is investing heavily in brain biomarker research, particularly for neurodegenerative diseases. Collaborations with international institutions are helping to validate biomarkers, and AI integration is improving data analysis capabilities. Rising mental health awareness is driving demand for more biomarker studies.
• Germany: Germany is at the forefront of brain biomarker development, with advancements in imaging technologies and a strong emphasis on clinical implementation. The country is also promoting deeper collaboration between industries and universities to drive innovation.
• India: India's brain biomarker market is expanding due to increased research activities in neurology and psychiatry. Researchers are focusing on low-cost biomarker discovery, which makes the technology more accessible to the local population. The increasing prevalence of neurological diseases is further driving demand.
• Japan: Japan is a leader in integrating AI technologies into brain biomarker research. The country is also advancing the use of biomarkers in clinical trials for neuro-stimulating drugs, improving patient outcomes and treatment efficacy.

Each of these countries is making significant contributions to the development of brain biomarkers, with a focus on improving diagnostic accuracy and therapeutic interventions for neurological diseases.

Features of the Global Brain Biomarker Market

Market Size Estimates: Brain biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Brain biomarker market size by various segments, such as by product type, disease indication, application, end use, and region in terms of value ($B).

Regional Analysis: Brain biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, disease indication, application, end use, and regions for the brain biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brain biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the brain biomarker market by product type (biomarker test kits and biomarker analyzers), disease indication (stroke, MND & ALS, Alzheimer's disease & other dementias, Parkinson's disease, and Huntington's disease), application (diagnosis, drug discovery and development, and others), end use (hospitals, research laboratories, ambulatory surgical centers, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Brain Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Brain Biomarker Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Brain Biomarker Market by Product Type
  • 3.3.1: Biomarker Test Kits
  • 3.3.2: Biomarker Analyzers
• 3.4: Global Brain Biomarker Market by Disease Indication
  • 3.4.1: Stroke
  • 3.4.2: MND & ALS
  • 3.4.3: Alzheimer's Disease & Other Dementias
  • 3.4.4: Parkinson's Disease
  • 3.4.5: Huntington's Disease
• 3.5: Global Brain Biomarker Market by Application
  • 3.5.1: Diagnosis
  • 3.5.2: Drug Discovery and Development
  • 3.5.3: Others
• 3.6: Global Brain Biomarker Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Research Laboratories
  • 3.6.3: Ambulatory Surgical Centers
  • 3.6.4: Diagnostic Laboratories
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Brain Biomarker Market by Region
• 4.2: North American Brain Biomarker Market
  • 4.2.1: North American Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.2.2: North American Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.3: European Brain Biomarker Market
  • 4.3.1: European Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.3.2: European Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.4: APAC Brain Biomarker Market
  • 4.4.1: APAC Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.4.2: APAC Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.5: ROW Brain Biomarker Market
  • 4.5.1: ROW Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.5.2: ROW Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Brain Biomarker Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Brain Biomarker Market by Disease Indication
  • 6.1.3: Growth Opportunities for the Global Brain Biomarker Market by Application
  • 6.1.4: Growth Opportunities for the Global Brain Biomarker Market by End Use
  • 6.1.5: Growth Opportunities for the Global Brain Biomarker Market by Region
• 6.2: Emerging Trends in the Global Brain Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Brain Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Brain Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Siemens Healthineers
• 7.2: Electrical Geodesics
• 7.3: Lifesign
• 7.4: Advanced Brain Monitoring
• 7.5: BrainScope
• 7.6: GE Healthcare
• 7.7: Johnson & Johnson
• 7.8: Natus Medical
• 7.9: F. Hoffmann-La Roche
• 7.10: Qiagen